Monday, September 25

7:45 am - 8:45 am
Industry-Sponsored Symposia (ISS)
Presented by BioreclamationIVT

In vitro Prediction of Drug Metabolism and Transport Using Primary Human Hepatocytes
Hongbing Wang

View the symposium content here.

9:00 am - 9:45 am
Plenary Lecture 1

Targeting The Achilles Heel of Cancer: Nutrient Transporters
Vadivel Ganapathy, Texas Tech University Health Sciences Center

10:15 am - 12:15 pm
Parallel Symposia 1 and 2

Symposium 1: Towards Understanding of Tissue Transporter Interactions: Impact on Drug Efficacy/Safety and Tissue Targeting
Chair: Aleksandra Galetin, University of Manchester

Tissue Transporter Drug-Drug Interactions: Safety/Efficacy Concerns Not Readily Apparent from Systemic Exposure
Aleksandra Galetin, University of Manchester

Integration of Imaging Techniques to Study Tissue Distribution of Drugs
Hiroyuki Kusuhara, University of Tokyo

Drug Efficacy Associated with Renal Apical Transporter
Caroline Lee, Ardea Biosciences

Renal Transporters:  Mediators of Drug Disposition and Action
Kathy Giacomini, University of California, San Francisco

Symposium 2: Drug Discovery and Development in the Trenches
Chairs: Cornelis (Marcel) Hop, Genentech and Natalie Hosea, Takeda

Venetoclax: DMPK Challenges and Opportunities from Discovery to Market
Daniel Bow, Abbvie

Challenges in Human Projections for Prodrugs: GS-6620 for HCV
Adrian Ray, Gilead

Development of Daclatasvir: Opportunities and Challenges Along the Way
Griff Humphreys, Bristol-Myers Squibb

ADME Challenges Encountered During the Development of Osimertinib; an Irreversible EGFR Inhibitor
Martin Wild, AstraZeneca

12:15 pm - 1:00 pm
Lunch and Visit with Exhibitors

1:00 pm - 2:00 pm
Poster Presentations and E-Poster Theater Session: Transporters

2:00 pm - 4:00 pm
Parallel Symposia 3 and 4

Symposium 3: Biomarkers of Safety and DDI (Transport and Metabolism)
Chairs: Yurong Lai, Gilead Science and Jose Manautou, University of Connecticut

Novel Genetic Determinants of Acetaminophen Toxicity with the Potential for Validation of Biomarkers
Jose Manautou, University of Connecticut

Endogenous Probes for Transporter-mediated Drug-Drug Interaction
Yurong Lai, Gilead Science

Novel Biomarkers in DILI: the Development of Novel DILI Biomarkers and Therapeutic Interventions
Daniel Antoine, University of Liverpool

Applications and Challenges of Using Endogenous Biomarkers for CYP DDI Evaluation
Yvonne Lin, University of Washington

    Symposium 4: When is a PBPK Model Fit for Purpose? Insights to Model Acceptance Criteria, Extrapolation to Different Populations, and Modeling Population Variability
    Chairs: Ping Zhao, Bill and Melinda Gates Foundation and Nina Isoherranen, University of Washington

    Industry perspective of FDA PBPK guidance and EMA PBPK guideline: report from IQC
    Hannah Jones, Pfizer

    Assessment of the Predictive Performance of PBPK Models
    Ping Zhao, Bill and Melinda Gates Foundation

    How Should a PBPK Model be Evaluated for Intended Use?
    Nina Isoherranen, University of Washington

    Hannah Jones, Nina Isoherranen, Lei Zhang, and Joseph Grillo

    4:00 pm - 4:30 pm
    Refreshment Break with Exhibitors

    4:30 pm - 6:00 pm
    Podium Presentations of Postdoctoral Poster Awards Finalists